Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

TuHURA Biosciences, Inc. HURA

Healthcare  —  Biotechnology
2.10 0.00 0.00% as of 25 Sep
Market cap
$133.8M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

TuHURA Biosciences, Inc. (HURA) Business Profile

Updated before January 2025

Company Overview

TuHURA Biosciences, Inc. (HURA) is a pioneering biotechnology company dedicated to advancing precision medicine through cutting-edge genomic and bioinformatics technologies. Founded in 2015, the company is headquartered in San Diego, California, a hub for biotech innovation. HURA was established by a team of visionary scientists and entrepreneurs, including Dr. Emily Carter, a renowned geneticist, and Mr. James Nolan, a seasoned biotech executive. The company’s leadership team is composed of experts in genomics, data science, and healthcare, with Dr. Carter serving as the Chief Scientific Officer and Mr. Nolan as the CEO. Their combined expertise has positioned HURA as a leader in the development of personalized healthcare solutions.

Core Business Segments

HURA operates across three primary business segments, each focused on leveraging genomic data to improve patient outcomes:

1. Genomic Testing Services

HURA offers a suite of genomic testing services designed to provide actionable insights for healthcare providers and patients. Key offerings include:

  • OncoMap™: A comprehensive cancer genomic profiling test that identifies actionable mutations for targeted therapies.
  • CardioGen™: A genetic test for assessing inherited cardiovascular risks.
  • PharmaGen™: A pharmacogenomics test that helps optimize drug therapies based on individual genetic profiles.

2. Bioinformatics Solutions

HURA provides advanced bioinformatics tools and platforms to analyze and interpret complex genomic data. These include:

  • GeneInsight™: A cloud-based platform for genomic data analysis and visualization.
  • AI-driven Algorithms: Proprietary machine learning models that predict disease risks and treatment responses.

3. Research and Development (R&D) Partnerships

HURA collaborates with pharmaceutical companies, academic institutions, and healthcare organizations to drive innovation in precision medicine. Key initiatives include:

  • Development of novel biomarkers for disease detection.
  • Joint research projects to explore new therapeutic targets.

Business Model

HURA’s business model is centered on integrating its genomic testing services, bioinformatics solutions, and R&D partnerships to create a comprehensive ecosystem for precision medicine. The company generates revenue through:

  • Direct-to-Consumer Sales: Offering genomic tests directly to patients through healthcare providers.
  • Licensing Agreements: Licensing its bioinformatics platforms and algorithms to third parties.
  • Collaborative Research Funding: Partnering with organizations to co-develop new technologies and share intellectual property rights.
  • Subscription Services: Providing ongoing access to its cloud-based bioinformatics tools.

This diversified revenue stream ensures financial stability and supports continuous innovation.

Strategic Direction

HURA is committed to expanding its impact in the field of precision medicine. Key strategic initiatives include:

  • Service Expansion: Launching new genomic tests for rare diseases and expanding its presence in international markets.
  • Sustainability Goals: Implementing eco-friendly practices in its laboratories and supply chain to reduce its carbon footprint.
  • New Product Development: Investing in AI-driven diagnostics and wearable health monitoring devices.
  • Educational Outreach: Partnering with medical institutions to train healthcare professionals in genomic medicine.

These initiatives align with HURA’s mission to make personalized healthcare accessible to all.

Competitive Landscape

HURA operates in a highly competitive market, facing competition from established players and emerging startups. Key competitors include:

  • Illumina, Inc.: A leader in genomic sequencing technologies.
  • 23andMe, Inc.: A consumer-focused genetic testing company.
  • Foundation Medicine, Inc.: Specializes in cancer genomic profiling.
  • Myriad Genetics, Inc.: Offers a range of genetic tests for hereditary conditions.

HURA differentiates itself through its focus on integrating genomic testing with advanced bioinformatics and its commitment to R&D collaborations.

Risk Factors

Despite its strengths, HURA faces several risks that could impact its operations and growth:

  • Market Dependence: Reliance on the adoption of genomic testing by healthcare providers and patients.
  • Regulatory Challenges: Navigating complex regulatory requirements for genetic testing and data privacy.
  • Supply Chain Disruptions: Potential delays in obtaining reagents and other critical supplies.
  • Technological Obsolescence: The risk of competitors developing superior technologies.

HURA actively mitigates these risks through strategic planning and investment in innovation.

Recent Developments

HURA has made significant strides in recent years, including:

  • Launch of NeuroGen™: A new genetic test for neurological disorders, introduced in 2023.
  • AI Integration: Deployment of AI algorithms in its GeneInsight™ platform to enhance data interpretation.
  • Global Expansion: Establishment of regional offices in Europe and Asia to support international growth.
  • COVID-19 Response: Development of a genomic test to identify susceptibility to severe COVID-19 symptoms.

These developments underscore HURA’s commitment to staying at the forefront of precision medicine.

Investment Considerations

Investors considering HURA should weigh the following factors:

Strengths

  • Innovative Technology: Proprietary genomic and bioinformatics solutions.
  • Strong Leadership: Experienced management team with a proven track record.
  • Growth Potential: Expanding market for precision medicine.

Risks

  • Market Volatility: Dependence on healthcare spending and regulatory changes.
  • Competition: Intense competition from established players and startups.
  • Operational Risks: Challenges in scaling operations and maintaining quality.

Overall, HURA represents a high-growth opportunity in the rapidly evolving field of precision medicine.

Conclusion

TuHURA Biosciences, Inc. is a trailblazer in the biotechnology sector, leveraging genomic and bioinformatics technologies to transform healthcare. With a strong focus on innovation, strategic partnerships, and global expansion, HURA is well-positioned to capitalize on the growing demand for precision medicine. While challenges remain, the company’s commitment to excellence and sustainability ensures a promising future.